BACKGROUND AND AIM: The aim of this study was to investigate the possible effect of a COX-2 inhibitor in addition to chemoradiation of locally advanced rectal cancer. MATERIALS AND METHODS: The study included 35 patients with rectal adenocarcinoma. All patients had a tumor localised <or=10 cm from the anal verge and a circumferential margin <or=5 mm on a magnetic resonance scan. The patients were scheduled to receive external radiation with a tumor dose of 60 Gy supplemented with an endorectal boost of 5 Gy. Concurrent with radiation, the patients received uracil-tegafur 300 mg/m(2) daily. Celexocib was scheduled throughout the radiation period in a dose of 400 mg x 2 daily. RESULTS: A macular papular rash was seen in 17 (49%) of the patients leading to stop of medication with celecoxib. Thirty-three patients were operated, and all patients responded to treatment. Complete pathological remission was found in 21% of the patients and further 24% had only microscopic residual tumor cells. The results did not suggest any difference according to the accomplishment of the COX-2 medication. CONCLUSION: The addition of a COX-2 inhibitor to chemotherapy-enhanced radiation treatment of rectal cancer was not feasible due to a high incidence of rash in the present study.
RCT Entities:
BACKGROUND AND AIM: The aim of this study was to investigate the possible effect of a COX-2 inhibitor in addition to chemoradiation of locally advanced rectal cancer. MATERIALS AND METHODS: The study included 35 patients with rectal adenocarcinoma. All patients had a tumor localised <or=10 cm from the anal verge and a circumferential margin <or=5 mm on a magnetic resonance scan. The patients were scheduled to receive external radiation with a tumor dose of 60 Gy supplemented with an endorectal boost of 5 Gy. Concurrent with radiation, the patients received uracil-tegafur 300 mg/m(2) daily. Celexocib was scheduled throughout the radiation period in a dose of 400 mg x 2 daily. RESULTS: A macular papular rash was seen in 17 (49%) of the patients leading to stop of medication with celecoxib. Thirty-three patients were operated, and all patients responded to treatment. Complete pathological remission was found in 21% of the patients and further 24% had only microscopic residual tumor cells. The results did not suggest any difference according to the accomplishment of the COX-2 medication. CONCLUSION: The addition of a COX-2 inhibitor to chemotherapy-enhanced radiation treatment of rectal cancer was not feasible due to a high incidence of rash in the present study.
Authors: Petra Anna Ohneseit; Guido Krebiehl; Klaus Dittmann; Rainer Kehlbach; Hans Peter Rodemann Journal: Radiother Oncol Date: 2007-01-04 Impact factor: 6.280
Authors: S J Dawson; M Michael; J Biagi; K F Foo; M Jefford; S Y Ngan; T Leong; A Hui; A D Milner; R J S Thomas; J R Zalcberg Journal: Invest New Drugs Date: 2006-10-20 Impact factor: 3.850
Authors: R G Beets-Tan; G L Beets; R F Vliegen; A G Kessels; H Van Boven; A De Bruine; M F von Meyenfeldt; C G Baeten; J M van Engelshoven Journal: Lancet Date: 2001-02-17 Impact factor: 79.321
Authors: Anders Jakobsen; John P Mortensen; Claus Bisgaard; Jan Lindebjerg; Johnny W Hansen; Søren R Rafaelsen Journal: Int J Radiat Oncol Biol Phys Date: 2005-10-13 Impact factor: 7.038